ArticleSurgical endoscopy2021
Transanal total mesorectal excision: the Slagelse experience 2013-2019.
Article in Surgical endoscopy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Multicenter phase II trial of transanal total mesorectal excision for rectal cancer: preliminary results.Surgical endoscopy · 2023Trial
- Long-term oncologic outcomes after transanal total mesorectal excision: a single-center cohort with a minimum of 5-year follow-up.Surgical endoscopy · 2026Article
- Comparative efficacy analysis of laparoscopic-assisted transanal total mesorectal excisionWorld journal of gastrointestinal surgery · 2025Article
- Oncologic outcomes following transanal total mesorectal excision: the United States experience.Surgical endoscopy · 2024Observational
- The role of transanal compared to laparoscopic total mesorectal excision (taTME vs. lapTME) for the treatment of mid-low rectal cancer in obese patients: outcomes of a multicenter propensity-matched analysis.Updates in surgery · 2023Observational
- Recurrence following transanal total mesorectal excision for rectal cancer: a monocentric retrospective series of technically difficult cases.Annals of coloproctology · 2023Article
- Simple transanal total mesorectal resection versus laparoscopic transabdominal total mesorectal resection for the treatment of low rectal cancer: a single-center retrospective case-control study.Frontiers in surgery · 2023Article
- The taTME learning curve for mid-low rectal cancer: a single-center experience in China.World journal of surgical oncology · 2022Article
- Three-year outcomes of transanal total mesorectal excision versus standard laparoscopic total mesorectal excision for mid and low rectal cancer.Surgical endoscopy · 2022Article
- Structured training curriculums for transanal total mesorectal excision in China: refinement is needed.Annals of translational medicine · 2022Article
- Limitations and Concerns with Transanal Total Mesorectal Excision for Rectal Cancer.Clinics in colon and rectal surgery · 2022Review
- Transanal total mesorectal excision outcomes for advanced rectal cancer in a complex surgical population.Surgical endoscopy · 2022Article
- Transanal total mesorectal excision for stage II or III rectal cancer: pattern of local recurrence in a tertiary referral center.Surgical endoscopy · 2021Article
- The learning curve of transanal total mesorectal excision for rectal cancer is associated with local recurrence: results from a multicentre external audit.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2021Article
- Oncological outcomes and stoma-free survival following TaTME, a prospective cohort study.Techniques in coloproctology · 2021Article
- Transanal total mesorectal excision: 3-year oncological outcomes.Techniques in coloproctology · 2021Article
- Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer.JAMA network open · 2021Article
- Clinical Status and Future Prospects of Transanal Total Mesorectal Excision.Frontiers in oncology · 2021Review
- Initial Experience with the Safe Implementation of Transanal Total Mesorectal Excision (TaTME) as a Standardized Procedure for Low Rectal Cancer.Journal of clinical medicine · 2020Article
- [Transanal total mesorectal excision-Indications, technique and results].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe outcomes after transanal total mesorectal excision (TaTME) 5 years from implementation at a large-volume colorectal unit, including local recurrence, distant metastasis, and survival.
backgroundTransanal total mesorectal excision (TaTME) is a relatively new procedure for mid- and low-rectal cancer, with well-documented safety and feasibility. However, data on long-term results are limited.
methodsThis study was based on a prospective data collection via a maintained database in a large colorectal unit. The database included patients who underwent TaTME from December 2013 through July 2019. We have updated the database through a review of patient charts, including radiology and pathology reports. Data collection included operative details, intraoperative findings, postoperative complications, pathologic results, and oncologic results.
resultsDuring the study period, two hundred patients underwent TaTME in the study period (men = 147). The mean BMI was 26.7%, and the mean tumor height from the anal verge was 7.86 cm. Neoadjuvant treatment was given to 22% of patients. Anastomotic leakage occurred in 9.3% of patients, and the overall rate of postoperative complications was 24.5%. The TME specimen was incomplete in 11% of patients, and the CRM was positive in 5.5% of patients. Local recurrence (LR) occurred in seven patients with a follow-up of at least 2 years (4.7%). Distant metastasis (DM) occurred in 12% of patients. The overall survival was 90% and disease-free survival was 81%. The operating time was reduced in the later period of our experience.
conclusionsThis study showed that TaTME is feasible, safe, and had acceptable short-term outcomes and an acceptable rate of LR. The study included, however, one group that was non-randomized, and the follow-up was not long enough for most patients. Studies with longer follow-up data are awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.